Valion Bio Loses President, COO and CFO Lisa Wolf in Single Resignation
VBIO is trading near its 52-week low of $0.472 (6.5% above the low) on light trading volume (0.1× avg).
Summary
Valion Bio's President, COO and CFO Lisa Wolf resigned on October 31, 2026, effective December 11, 2026, leaving three senior roles vacant with no successor disclosed. It is the second top-executive exit since the August CEO termination.
Key Events · Executive and Board Changes · VBIO
-
President, COO and CFO Resigns
Lisa Wolf notified the board's Special Committee on October 31, 2026 of her voluntary resignation from all three roles, effective December 11, 2026. The resignation is not yet effective as of this filing.
-
Three Roles Left Without Successors
The 8-K names no replacement for President, COO or CFO. Interim CEO Dean Zikria signed the filing, meaning he currently covers the CEO seat while the operating and finance functions lose their head.
-
Second Top Exit Since August
Follows the August 17, 2026 termination of the CEO and appointment of a COO, a shakeup pushed by activist 3i, LP, which now beneficially owns 46.17% per the October 16, 2026 S-3.
-
Five-Week Transition Window
Departure takes effect December 11, 2026, giving the board roughly five weeks to appoint a CFO before the company must report again with going-concern doubt and cash that stood at $2.1M at June 30.
Analysis · VBIO · Life Sciences
One person held three of the top operating jobs, and she is leaving all of them on December 11, 2026, with no successor named in the filing. That is a serious hole for a company that already replaced its CEO in August at activist investor 3i's insistence, is burning roughly $7.1M a quarter, and has going-concern doubt on the record. The interim CEO, Dean Zikria, now absorbs the CEO, President, COO and CFO functions at once — exactly the thin-management condition that makes closing the Velocity Bioworks sale and staying Nasdaq-compliant harder. The resignation is voluntary and not yet effective, so there is a five-week window to name replacements; the filing does not say whether any search is underway.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VBIO was trading at $0.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.47 to $67.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.